Watch our webinar with Cynata Therapeutics, featuring Managing Director and CEO Dr Kilian Kelly. A presentation followed by live Q&A with the audience.

Cynata is commercialising Cymerus™ - a platform that produces Mesenchymal Stem Cells (MSCs) at scale. MSCs are potent immune-modulating and tissue-repairing cells, but naturally scarce in the human body. Traditional manufacturing depends on constant donors and suffers from inconsistency, potency loss, and limited scalability. Cymerus™ removes this bottleneck and unlocks true therapeutic and commercial potential.
The company has 3 clinical programs underway and major Phase 2 and Phase 3 readouts due in the next 6-9 months. Earlier clinical results already demonstrate strong safety and efficacy, giving investors a rare evidence-based confidence as they move into these pivotal late-stage milestones.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.